Vaughan David Investments’s AbbVie ABBV Stock Holding History

Vaughan David Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83.2M	Sell	330,587 -2,030	-0.6%	-$437K	1.66%	8
2026 Q1	$72.3M	Sell	332,617 -183	-0.1%	-$40.6K	1.53%	8
2025 Q4	$76M	Sell	332,800 -3,664	-1%	-$835K	1.65%	8
2025 Q3	$77.9M	Sell	336,464 -8,803	-3%	-$1.79M	1.68%	7
2025 Q2	$64.1M	Buy	345,267 +1,013	+0.3%	+$188K	1.43%	10
2025 Q1	$72.1M	Sell	344,254 -10,233	-3%	-$1.99M	1.69%	7
2024 Q4	$63M	Buy	354,487 +195	+0.1%	+$35.9K	1.49%	10
2024 Q3	$70M	Sell	354,292 -1,879	-0.5%	-$351K	1.61%	7
2024 Q2	$61.1M	Buy	356,171 +154	+0%	+$25.5K	1.55%	11
2024 Q1	$64.8M	Sell	356,017 -223	-0.1%	-$38.4K	1.61%	7
2023 Q4	$55.2M	Buy	356,240 +2,903	+0.8%	+$423K	1.51%	8
2023 Q3	$52.7M	Buy	353,337 +2,715	+0.8%	+$399K	1.59%	8
2023 Q2	$47.2M	Buy	350,622 +1,511	+0.4%	+$222K	1.38%	14
2023 Q1	$55.6M	Sell	349,111 -3,170	-0.9%	-$485K	1.68%	4
2022 Q4	$56.9M	Sell	352,281 -1,896	-0.5%	-$291K	1.69%	5
2022 Q3	$47.5M	Buy	354,177 +2,596	+0.7%	+$373K	1.59%	7
2022 Q2	$53.8M	Buy	351,581 +3,742	+1%	+$572K	1.72%	3
2022 Q1	$56.4M	Buy	347,839 +806	+0.2%	+$117K	1.66%	4
2021 Q4	$47M	Buy	347,033 +3,772	+1%	+$446K	1.37%	15
2021 Q3	$37M	Buy	343,261 +2,412	+0.7%	+$276K	1.18%	26
2021 Q2	$38.4M	Buy	340,849 +14,071	+4%	+$1.58M	1.2%	26
2021 Q1	$35.4M	Buy	326,778 +15,900	+5%	+$1.7M	1.12%	31
2020 Q4	$33.3M	Buy	310,878 +7,123	+2%	+$685K	1.14%	28
2020 Q3	$26.6M	Buy	303,755 +5,170	+2%	+$487K	1.03%	38
2020 Q2	$29.3M	Buy	298,585 +12,700	+4%	+$1.12M	1.2%	27
2020 Q1	$21.8M	Buy	285,885 +264,433	+1,233%	+$22.5M	1.01%	39
2019 Q4	$1.9M	Sell	21,452 -104	-0.5%	-$8.63K	0.07%	98
2019 Q3	$1.63M	Sell	21,556 -662	-3%	-$45.4K	0.06%	101
2019 Q2	$1.62M	Sell	22,218 -50	-0.2%	-$3.93K	0.06%	101
2019 Q1	$1.79M	Buy	22,268 +498	+2%	+$40.7K	0.08%	100
2018 Q4	$2.01M	Sell	21,770 -282	-1%	-$24.8K	0.09%	94
2018 Q3	$2.09M	Sell	22,052 -674	-3%	-$63.9K	0.09%	93
2018 Q2	$2.11M	Buy	22,726 +167	+0.7%	+$16.3K	0.1%	90
2018 Q1	$2.13M	Sell	22,559 -598	-3%	-$65.7K	0.1%	88
2017 Q4	$2.24M	Buy	23,157 +450	+2%	+$42.4K	0.1%	87
2017 Q3	$2.02M	Sell	22,707 -179	-0.8%	-$13.6K	0.1%	92
2017 Q2	$1.66M	Sell	22,886 -285	-1%	-$19.2K	0.08%	93
2017 Q1	$1.51M	Sell	23,171 -1,093	-5%	-$68.7K	0.08%	95
2016 Q4	$1.52M	Buy	24,264 +550	+2%	+$33.6K	0.08%	93
2016 Q3	$1.5M	Buy	23,714 +2,083	+10%	+$135K	0.08%	94
2016 Q2	$1.34M	Sell	21,631 -956	-4%	-$58.3K	0.07%	96
2016 Q1	$1.29M	Buy	22,587 +1,993	+10%	+$111K	0.07%	97
2015 Q4	$1.22M	Sell	20,594 -10,092	-33%	-$581K	0.07%	94
2015 Q3	$1.67M	Sell	30,686 -17,729	-37%	-$1.15M	0.11%	90
2015 Q2	$3.25M	Sell	48,415 -10,893	-18%	-$711K	0.19%	85
2015 Q1	$3.47M	Sell	59,308 -9,438	-14%	-$570K	0.21%	83
2014 Q4	$4.5M	Buy	68,746 +5,552	+9%	+$350K	0.26%	84
2014 Q3	$3.65M	Buy	63,194 +38,176	+153%	+$2.12M	0.22%	84
2014 Q2	$1.41M	Buy	25,018 +418	+2%	+$21.9K	0.08%	92
2014 Q1	$1.26M	Sell	24,600 -656	-3%	-$33.2K	0.08%	93
2013 Q4	$1.33M	Buy	25,256 +529	+2%	+$26K	0.09%	93
2013 Q3	$1.11M	Sell	24,727 -862	-3%	-$38.2K	0.08%	94
2013 Q2	$1.06M	Buy	+25,589	New	+$1.12M	0.07%	94

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vaughan David Investments's ABBV Position: Q2 2026 in Review

Vaughan David Investments reduced its AbbVie (ABBV) stake by 0.61% in Q2 2026, selling an estimated $437K and leaving 330,587 shares worth $83.2M. The position accounts for 1.66% of the portfolio, ranked #8.

Vaughan David Investments first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Vaughan David Investments held 330,587 shares of AbbVie worth $83.2M as of Q2 2026.
Vaughan David Investments sold 2,030 AbbVie shares in Q2 2026, an estimated $437K.
AbbVie made up 1.66% of Vaughan David Investments's portfolio in Q2 2026, its #8 holding.
Vaughan David Investments first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Vaughan David Investments's 13F filing for Q2 2026, filed 11 Aug 2026.